Bioregulators

Pinealon

Also known as: EDR, Glu-Asp-Arg

Preclinical
Share:

Buy in shop

Pinealon from $64/kit

4 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: Pinealon

Category
Bioregulators
FDA Status
Not FDA Approved
Clinical Status
Available in Russia - Not FDA approved
Administration
Oral or sublingual
Typical Dose
10-20 mg daily
Frequency
Once daily, typically evening
Duration
10-30 day courses
Also Known As
EDR, Glu-Asp-Arg

Mechanism of Action

Pinealon (EDR) is one of the short peptides identified in pineal and brain peptide preparations, and like other Khavinson bioregulators it is proposed to work as an epigenetic regulator that enters cells and influences gene expression and protein synthesis. In neuronal cell models it reduces the buildup of reactive oxygen species under oxidative stress, which is the basis for calling it an antioxidant and stress-protector. Reported downstream effects include less necrotic and apoptotic cell death and altered timing of ERK 1/2 signaling and the cell cycle. These are plausible, repeatedly reported in vitro findings, but the idea that such tiny peptides selectively reprogram gene expression in living human brains should be read as a hypothesis that has not been confirmed in people.

Research Summary

The research on pinealon is preclinical and concentrated in Russian peptide-bioregulator literature. In cultured cells, including cerebellar granule neurons, neutrophils and PC12 cells, pinealon dose-dependently limited oxidative-stress-induced ROS accumulation and reduced cell death, and it has been reported to increase cell viability and activate proliferative processes. Related work on the EDR peptide describes neuroprotective gene-expression effects in in vitro and in vivo Alzheimer's-type models, and pinealon is noted to share activity with the brain-peptide drug Cortexin. There are no published randomized human trials, no human safety or pharmacokinetic data, and most of the supporting work originates from a narrow cluster of affiliated groups rather than broad independent replication. The honest bottom line is that pinealon has consistent antioxidant and cell-protective signals in laboratory models and an essentially empty human evidence file.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Animal Studies·Primarily animal/preclinical research

Note: Animal study doses may not translate directly to humans.

Typical Dosing

Community experience

Common Dose

10-20 mg daily

Range

10-20 mg daily

Frequency

Once daily, typically evening

Brain bioregulator targeting pineal gland. Take in evening. Part of Khavinson peptide system.

Research Dosing

Scientific studies

Doses from research protocols

Duration

10-30 day courses

Administration

Oral or sublingual

Timing & Administration

Best Time to Take

Evening or before bed

Once daily before bed

Food Recommendation

With or without food

Why This Timing?

Pinealon affects the pineal gland and sleep regulation. Evening use supports natural melatonin.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally well-tolerated
  • Headache
  • Nausea
  • Dizziness
  • Vivid dreams
  • Injection site reactions
  • Caution with seizure disorders

References

Research This Peptide Further

Buy in shop

Pinealon from $64/kit

4 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Pinealon do?

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (the EDR peptide), from the Russian peptide-bioregulator family designed to mimic short signaling peptides found in brain tissue. It is studied as a neuroprotective and antioxidant compound, with researchers proposing it protects neurons from oxidative stress and supports cognition. Be clear-eyed about the evidence: it is essentially all cell-culture and animal work from a small set of related labs, with no human clinical trials and no regulatory approval.

How does Pinealon work?

Pinealon (EDR) is one of the short peptides identified in pineal and brain peptide preparations, and like other Khavinson bioregulators it is proposed to work as an epigenetic regulator that enters cells and influences gene expression and protein synthesis. In neuronal cell models it reduces the buildup of reactive oxygen species under oxidative stress, which is the basis for calling it an antioxidant and stress-protector. Reported downstream effects include less necrotic and apoptotic cell death and altered timing of ERK 1/2 signaling and the cell cycle. These are plausible, repeatedly reported in vitro findings, but the idea that such tiny peptides selectively reprogram gene expression in living human brains should be read as a hypothesis that has not been confirmed in people.

Is Pinealon FDA approved?

No, Pinealon is not currently FDA approved. Current status: Available in Russia - Not FDA approved

What are the side effects of Pinealon?

Reported side effects include: Generally well-tolerated, Headache, Nausea, Dizziness, Vivid dreams. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Pinealon?

Community-reported common dose: 10-20 mg daily (Once daily, typically evening). Range: 10-20 mg daily. Administration: Oral or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Pinealon or used in similar applications.

Epithalon

Clinical Trials

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), modeled on a natural pineal gland extract. It came out of decades of Russian gerontology research led by Vladimir Khavinson and is marketed as an anti-aging compound that supposedly switches telomerase back on. It has no approval from the FDA, EMA, or other Western regulators, and the human evidence is thin.

Bioregulators

Cortagen

Preclinical

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.

Bioregulators

Chonluten

Preclinical

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.

Bioregulators

Thymalin

Clinical Trials

Thymalin is not a single peptide but a polypeptide complex extracted from calf thymus, developed in the Soviet and Russian peptide-bioregulator tradition associated with Vladimir Khavinson. It is used in Russia and several post-Soviet countries to correct immune deficiency and is promoted as a geroprotector, with claimed effects on T and B lymphocytes, infection rates and aging. Outside that region it has no FDA or EMA approval, and the strongest human data come from a small number of studies, several from the originating research groups.

Bioregulators

Vilon

Preclinical

Vilon is a synthetic dipeptide, Lys-Glu (lysine-glutamic acid), one of the short peptide bioregulators developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is marketed in the anti-aging and immune-support space as a thymus-related bioregulator, but the real evidence base is almost entirely Russian animal studies. There are no registered Western randomized human clinical trials, so any human claims should be read with heavy skepticism.

Bioregulators

Cartalax

Preclinical

Cartalax is a synthetic tripeptide (Ala-Glu-Asp, or AED) from the Khavinson family of short peptide bioregulators, studied as a cartilage and connective-tissue regulator. It is a research compound, not an approved drug, and no registered human clinical trials exist.

Bioregulators

Want updates on Pinealon research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.